| abstract |
The present invention is based on melanin aggregation hormone receptor (MCH receptor) antagonism, depressive disorder, anxiety disorder (general anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive compulsive disorder or social anxiety disorder), attention deficit disorder, mania, Manic-depressive disorder, ataxia, mood disorder, stress, sleep disorder, seizure, memory impairment, cognitive disorder, dementia, forgetfulness, delirium, obesity, eating disorder, appetite disorder, bulimia, bulimia, anorexia, diabetes, cardiovascular disease, high blood pressure, Novel compounds, pharmaceutically acceptable salts or hydrates thereof, useful for the prevention or treatment of dyslipidemia, myocardial infarction, motor disorders (Parkinson's disease, epilepsy, convulsions or hydration), drug abuse, drug addiction or sexual dysfunction. The present invention relates to a compound represented by the formula (I), a pharmaceutically acceptable salt or a hydrate thereof. |